Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CML. Whether low dose IM in combination with agents...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Hu, Zheng, Pan, Xiao-Fen, Wu, Fu-Qun, Ma, Li-Yuan, Liu, Da-Peng, Liu, Ying, Feng, Ting-Ting, Meng, Fan-Yi, Liu, Xiao-Li, Jiang, Qian-Li, Chen, Xiao-Qin, Liu, Jing-Lei, Liu, Ping, Chen, Zhu, Chen, Sai-Juan, Zhou, Guang-Biao
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2009
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2705802/
https://ncbi.nlm.nih.gov/pubmed/19606213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0006257
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller